McKesson and private equity firm CD&R are acquiring Option Care Health for $5.8 billion, with McKesson taking a 49% minority stake and an option for future full acquisition. This strategic move significantly expands McKesson's presence in complex specialty, rare, and orphan therapies, while Option Care Health shareholders receive a 37% premium, though analysts suggest the valuation is low given its potential.
McKesson Corporation and CD&R are acquiring Option Care Health Inc. for $32.05 per share, valuing the company at $5.8 billion. This represents a substantial 37% premium for OPCH shareholders, leading to a positive short-term price action for OPCH. For MCK, this acquisition is a strategic long-term play, expanding its footprint in the high-growth complex specialty, rare, and orphan therapies market, aligning with its objective to become an embedded healthcare technology partner. While one analyst viewed the valuation as low for OPCH, suggesting potential competing bids, the deal solidifies MCK's competitive moat. The structure also provides MCK with an option for future full acquisition, indicating a clear long-term growth strategy.